Alan Fuhrman - Jan 1, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Financial Officer
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
4
Date filed
1/3/2023, 04:01 PM
Previous filing
May 31, 2022
Next filing
May 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Award $0 +32.8K $0.00 32.8K Jan 1, 2023 Common Stock 32.8K $7.60 Direct F1, F2
transaction TYRA Stock Option (Right to Buy) Award $0 +328K $0.00 328K Jan 1, 2023 Common Stock 328K $7.60 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 1, 2024, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2 The option vests based on achievement of a performance objective.